Thank you, ladies and gentlemen, for standing by. Welcome to the Boston Scientific Q1 2015 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Instructions will be given at that time. [Operator Instructions]. As a reminder, this conference is being recorded. I will now turn the conference over to our host, Ms. Lisa. Please go ahead.

Thank you, Karen. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer. We issued a press release earlier this morning announcing our Q1 2015 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our Web site under the heading, Financial Information. The duration of this morning's call will be approximately 45 minutes, slightly shorter than usual due to our upcoming Investor Day this Friday, May 1. Mike will begin our prepared remarks with an update on our business progress and his perspectives on the quarter. Dan will then review our overall Q1 2015 financial results as well as guidance for full year 2015 and Q2 2015. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. Before we begin, I’d like to remind everyone that this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words. They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q2 and full year 2015 guidance; as well as our tax rates, R&D spend and other expenses. Actual results may differ materially from those discussed in the forward-looking statements. Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs and 8-Ks filed with the SEC. These statements speak only as of today's date and we disclaim any intention or obligation to update them. At this point, I’ll turn it over to Mike for his comments. Mike?

Thank you, Susie. Good morning, everyone. Boston Scientific started off 2015 with solid results in the first quarter, as the company continued to deliver and build global momentum. We delivered 6% operating revenue growth and 18% year-over-year adjusted EPS growth, excluding a $0.02 negative impact for foreign exchange. We believe that we’re poised to continue the strong execution and in first quarter we announced several new important product approvals and M&A transactions. These improved acquisition at the AMS urology portfolio and the endoscopic ultrasound capabilities of Xlumena, and our recently announced China joint venture with Frankenman Corporation. We’re also pleased with the recent FDA approvals of our WATCHMAN left atrial appendage closure platform and the next-generation EMBLEM S-ICD platform. All of these things reinforce our belief that Boston Scientific is well positioned to deliver at or above market revenue growth, and despite the increased currency headwinds, we maintain our goal of consistent double-digit adjusted EPS growth through our ongoing operating margin improvement initiatives. I’ll provide some brief highlights of our first quarter but I’ll save the comments on our longer term outlook for the Investor Day this Friday. Dan will review the financials and second quarter guidance and then we’ll take your questions. So please note that in my remarks, all references to growth on a year-over-year basis in constant currency unless otherwise specified. In terms of the key highlights for the quarter, we delivered 6% operational revenue growth, strong operating margin expansion of 250 basis points versus first quarter 2014 and delivered adjusted EPS growth, excluding currency of 18%. Lastly, we strengthened and diversified our portfolio through new product approvals and M&A. Our results were driven by strong operational revenue growth at all three of our reporting segments; Cardiovascular up 10%, Rhythm Management up 4% and MedSurg up 4%.…

Thanks, Mike. I’ll start with some overall perspective on the quarter before getting into the details. We generated adjusted EPS of $0.21 achieving the high end of our guidance range of $0.19 to $0.21 and representing 6% year-over-year growth. Unfavorable foreign exchange impacted Q1 adjusted EPS by $0.02 versus the $0.01 we had assumed in our Q1 guidance range. Excluding this unfavorable foreign exchange impact, Q1 adjusted EPS grew 18% year-over-year. The strong performance in Q1 was driven primarily by operational revenue growth and gross margin expansion. Our Q1 2015 adjusted operating margin of 22.5% achieved the high end of our full year adjusted operating margin guidance range and represents improvement of 250 basis points over Q1 of 2014. We continue to execute against our goals of consistent revenue growth and operating margin expansion, and despite the significant FX headwinds, our goal for full year 2015 remains double-digit adjusted EPS growth. Now I’ll provide a more detailed review of our Q1 business performance and operating results. Unless stated otherwise, references to quarterly results increasing or decreasing are in comparison to the first quarter of 2014 and all revenue growth rates are given on a year-over-year constant currency basis. For the first quarter of 2015, consolidated revenue of 1.768 billion represented operational revenue growth of 6%, which excludes the impact of foreign exchange and the divested Neurovascular business. On an as reported basis, revenue was flat year-over-year. Excluding an approximate 160 basis point contribution from the Bayer Interventional acquisition, organic revenue growth was 5% in the quarter. The foreign exchange impact on sales was a $117 million headwind compared to the prior year period, about $27 million worse than we assumed in our prior guidance range. I’ll now provide more details on the revenue results for our seven businesses, which roll…

Thanks, Dan. Karen, let's open it up to questions for the next 20 minutes or so. In order to enable us to take as many questions as possible, please limit yourself to one question and one related follow-up. Karen, please go ahead.

Thank you. [Operator Instructions]. We’ll go to Bob Hopkins, Bank of America, please go ahead.

Thanks. I appreciate you taking the question. So two quick things. First, I heard a litigation update there on mesh, and I was wondering I might have missed the numbers. I’m just curious how many cases did that settlement represent? And then how many cases remain outstanding?

Thanks, Bob. What it represents is 2,970 cases that the conditional settlement will cover.

Next we’ll go to Mike Weinstein, JPMorgan, please go ahead.

Wow, I hope I can get in my one question. So I’ll ask maybe two questions before she cuts off. So first, could you just talk a little bit about the absorption of FX over the balance of the year and what are the offsets as you’re absorbing the FX headwind? And then I think you gave a LOTUS commentary really for the first time, you talked about 31% sequential growth for LOTUS. I know they’re small numbers still, but could you give us a sense of where revenues stand today? Thanks.

Sure, Mike. I’ll take the FX question. So as I mentioned, the initial guidance we gave was $0.04 of FX headwind at the EPS line, and now we see that as $0.06 to $0.07. So don’t feel like it’s important. Our goal I still double-digit EPS growth, so we hold the EPS range at $0.88 to $0.92 and we’ll look to make tradeoffs in other parts of the P&L to offset that and still deliver within the $0.88 to $0.92, because at the high end of that range at $0.92 that’s still double digit for the year versus last year. So basically tradeoffs within the rest of the P&L.

David Lewis, Morgan Stanley --

I’ll just continue to comment just briefly on the LOTUS, we’ll have quite a bit of time devoted to that on Friday during the Investor Day. At Investor Day we’ll actually give targets for 2015 in our structural heart business as well as 2016. So we’ll provide some more financial detail about an hour [ph] update there in terms of LOTUS. But overall, the program continues to build. We’re enrolling our U.S. IDE trial REPRISE III. We expect to have the trial enrolled by year-end 2015 and we continue to gain share in accounts that we’re selling in Europe. But we’ll provide a more detailed update on Friday.

David Lewis, Morgan Stanley, please go ahead.

Karen?

Yes, ma’am.

Yes, can you just allow them time for one follow-up question.

Sure. Ma’am, I’m sorry.

That’s okay. Thank you.

Great. Thanks. Good morning. So two questions. I guess, Dan, the first one, you were just coming back to margins. Looking at the last two quarters, 200 basis points year-on-year in the fourth quarter, 250 basis points this quarter. I appreciate there’s some currency in those numbers and hedging gains, but you appear to be tracking well in excess of the more than 100 basis points you need to get to 25% in '17. So, is that a fair estimation that based on the results of last six months, you certainly are tracking above expectations that would get you to 25% in '17?

Thanks, David. I think the way I’d describe that is that we have good visibility to getting to that 25%. And we think last year, we ended at 20%, 20.2%. And then 2017 is the 25%, so we need to average more than 100 basis points per year in order to get to that 25% number in 2017. And obviously are very focused on doing that. We did raise the low end of the operating margin guidance range for the full year to 22%, from 21.5%. So now our guidance is 22% to 22.5% for this year. And feel like that’s appropriate. Q2 should be a little bit lower, as I mentioned that. It should be between 21% and 22%. It’s historically as it was last year, the lowest OI quarter in a particular year given a lot of incremental trade show and Congress spending with HRS and PCR and DDW and a bunch of others. So look for that to go down in Q2 and then feel comfortable with the 22% to 22.5% this year, and good visibility to the 25% in '17.

Okay. Mike, just a quick one for you. This is an interesting quarter because we saw multiple distribution deals out of the company; Brainlab, Bard, Frankenman. Are these all just one-off deals or is this a trend in terms of where you want to spend your time and money across different products, different regions, and is it related at all to how you think about your margin expansion goals over the next two to three years? Thank you.

Yes. So we want to grow faster than the market and expand our margin throughout, double-digit EPS growth. And I think when you look at the rationale for many of those deals, it’s really about driving category of leadership and being the preferred clinical partner to our physicians. So take the Brainlab example. So we have a terrific spinal cord stimulation business. We’re very early with we think is a disruptive deep brain stimulation portfolio that we’re enrolling the IDE trial now in the U.S. and we’re approved in Europe. But we don’t have as much scale in the neuro industry. So Brainlab has an excellent relationship with neurosurgeons. They have excellent guidance in mapping capabilities and so they will prove to be a smart distributor for us to align with to help build our commercial capabilities and broaden the depth of that portfolio. Similar with Bard, we have we believe the strongest portfolio in peripheral vascular. We recently acquired the Bayer division, atherectomy and thrombectomy and you saw the breakthrough results in our early results of our drug-eluting stent trial in terms of patency rates. But we feel that the Bard alliance is a great complement to that. It brings us into the U.S. sales capability now with the drug-eluting balloon. And so we really use these JVs to help fill in potential areas in the portfolio that maybe gaps as we continue to drive category of leadership.

Thank you. Rick Wise, Stifel, please go ahead.

Good morning, everybody. Maybe Dan, just to start with you, can you talk – can you break down, give us a little more color on the operating segment performance. Obviously, Cardiovascular outstanding sequentially year-over-year, Rhythm Management excellent year-over-year, a little lower sequentially; MedSurg a little weaker. I’m not sure I understand the drivers behind each. Can you give us a little more there?

Sure. I think starting with the Rhythm Management one, I think that’s what you’ve seen over the last 12 to 18 months, and that’s more than 100 basis points per quarter increases in Rhythm Management and again that’s a huge focus for Joe Fitzgerald and the team there. So I think that’s for Q1. It’s in line with what you’ve seen in terms of the activities that are driving that. CV obviously with the more than 600 basis points, that’s a bit of an anomaly. That generally is in the mid to high 20s. So that’s driven by a favorable product mix within IC, as you would expect. When drug-eluting stents do well and when overall the mix within IC does well, that drives more profitability within IC. I wouldn’t expect to see 30.6 going forward. I’d expect that to go back into the more traditional mid to high 20s. But obviously pleased to see that, given the mix that we had in the quarter. And the MedSurg, that’s lower than you’d expect to see at the 29. But overall, again, not a worry there. The growth was a little bit slower in urology at 3% and endoscopy at 4%. They drive – particularly endoscopy drives a significant amount of the profitability in the MedSurg franchise. As Mike and I both mentioned, we look for those numbers from a growth perspective to increase in Q2 and in the back half and that should take care of the MedSurg. I’m not worried about the MedSurg profitability.

Okay. And Mike, just a strategic question building on David Lewis’ question a little bit. You talked about tuck-in M&A as a priority. Obviously, you keep steadily adding to the portfolio in multiple ways. Can you just give us your latest thoughts on – I mean are you looking for tuck-in deals, are you looking for technology, are you looking for O-U.S. more than U.S.? How do we think about your priorities? Are you just being opportunistic?

I think we’re being pretty efficient. The performance of top line growth at 6 [ph], EPS growth ex-FX at 18 and strong margin improvement 250. And so really it goes back to the strategy of category leadership. And so we want to make sure the acquisitions we look at, it fits our strategic rationale and deliver strong financial returns. The AMS acquisition certainly meets this criteria in terms of nearly doubling the sales growth and ROIC that hits our targets at year three. And some of these alliances are a very cost effective way to extend our category leadership globally, whether it’d be the Bard alliance that we talked about or Brainlab. The Frankenman JV, we’re excited about it. It’s our first JV into China. That business has been growing plus 25% and gives us stronger local capabilities that will build on our R&D and manufacturing capabilities, and we think it will accelerate the growth in endoscopy. So we’re also very active in early private equity venture activity. So all these point towards either alliances, JVs or acquisitions that reinforce our category leadership goal and driving growth at or faster than market and driving margin improvement.

Thank you. Bruce Nudell, Credit Suisse, please go ahead.

Hi, guys. This is Matt in for Bruce. Can you hear me okay?

Yes, Matt.

Can hear you fine, Matt, yes.

Great. So it looks like just on top line guidance, FX got worse. Excluding that, you raised the top in 15 million to 65 million, somewhere in there, and I wondered if you can comment on what’s driving that, and specifically around what magnitude of sales you’re expecting from these recent partnerships and acquisitions; Brainlab, Frankenman, Bard, Xlumena?

We continue to see very strong growth in our core business. The majority of our business is growing faster than market based on recently approved pipeline. We had, as you know, the EMBLEM product in CRM recently approved. We’ll launch that in a more meaningful way in second half of the year. So we expect to see strong uptick of that, the WATCHMAN approval; so very strong cadence of product approvals in our core business. We’ll have synergy approved hopefully in fourth quarter in the U.S. And then consistent with our strat plan, we’re moving into some new adjacencies. Our TAVR portfolio is beginning to pick up, increased traction in Europe and we continue to strengthen our EP business. As Dan talked about, we’re not quite there yet but we did 6% in the quarter in EP and we’re beginning to build capabilities in mapping and make some advances in our therapeutic catheter line. So we kind of walked through all of the businesses, but essentially we’re pleased that in most of our business we continue to grow faster than market based on innovation and strong commercial performance. And many of our exciting pipeline therapies will be discussed this Friday and that gives us quite a bit of confidence as we look out over the longer term period, the strat plan.

Thanks. And just one follow up on the S-ICD. You’ve talked in the past about commercial coverage. Can you remind us sort of how far along you are there and are you kind of – when you get to 100% or as close to that as you expect to end up?

I’m not sure you ever get to 100%, Matt. We’ve had some good wins as we exited 2014 and into the first quarter of '15, so feel like that’s becoming less of a headwind on that relative to the S-ICD.

Thank you. Larry Biegelsen, Wells Fargo, please go ahead.

Hi, guys. Thanks for taking the question. Just two numbers that you normally give us, I didn’t see in the release, U.S. DES growth and emerging market growth this quarter. And I had a follow up.

Larry, this is Dan. So on the DES, I think that’s a trend for us just from a competitive perspective and the fact that we’re obviously a lot more diversified than we were when we started that process many, many years, I think we’ll give the global number and then potentially some growth rates, but not the specific numbers similar to some of our competitors on the DES front.

So no U.S. DES growth, Dan?

We did give – we said it was low double digit, I believe – in double digits.

That’s U.S.?

That was O-U.S.

Got it, all right. And then emerging markets, Dan?

We didn’t give the specific emerging markets. I know Mike quoted a couple of specifics within countries with China in the mid 20s, but nothing specific.

I did say it was 7% global DES growth and very balanced across the regions.

All right, that’s helpful. And then for my follow up, I’m trying to understand what’s in the guidance, Dan. So you did 5% organic this quarter by my math and my math might be wrong. We have 2% to 4% organic for the second quarter and I guess what is the full year organic growth – what’s included for acquisitions? Is AMS in that new number or is that excluding AMS? And if it includes AMS, it looks like the organic growth rate that’s implied for Q2 and for full year 2015, I recognize AMS isn’t expected to close until the third quarter would be below the 5% that you did this quarter. So maybe if you could kind of just bridge what’s in the guidance and what your kind of organic growth expectations are, that would be helpful. Thanks.

The easy one is we don’t include AMS until that acquisition closes. So that is out of our guidance going forward until that acquisition would close. As you think of the rest of the year, particularly as you get into Q3 and Q4, there are some much more challenging comps particularly in IC. So we grew overall as a company. Operationally we grew 7% in Q3 and 7% in Q4. So the comps get a little more difficult as we get into the back half of the year, so feel like that 4% to 6% operational growth which would be 3% to 5% for the full year is a good number for organic growth.

3% to 5%, that’s fair.

Yes, 3% to 5% organic, which we describe as excluding the acquisition – excluding Bayer would be 3% to 5% and operational 4% to 6% for the full year.

Thank you. Bob Hopkins, Bank of America, please go ahead.

Sorry about that. So just the one follow up I wanted to ask was on the endo business. Obviously, that’s been a very consistent grower for you guys. It was maybe slightly below what we were looking for this quarter, so maybe just some commentary this quarter. And much more importantly, some commentary on do you think that this is a business that can sustain at least mid-single digit growth, so just some comments on this division. Thank you.

It’s Mike. We have a lot of confidence in the endoscopy business. Dave will highlight it for about 20 minutes on Friday. So last year, we grew 5%. First quarter, we’re down a little bit, 4%. We have a number of new product launches that just really are in process right now with the digital SPYGLASS being the primary one, which is beginning to ramp up in terms of its deliverability. And also some launches that Dave will discuss in the second half. So we have quite a bit of confidence that our endoscopy business will continue to be a strong mid-single digit grower and continue to drive operating margin improvement potentially with some upside in the emerging markets with the Xlumena acquisition and the Frankenman JV.

Great. We’ll see you Friday.

Thanks, Bob.

Karen, we’ll take two more please.

Brooks West, Piper Jaffray, please go ahead.

Hi. Thanks for taking the questions. Just two quick ones from me. Dan, you said AMS wasn’t in the guidance. If we did want to add that to our numbers, you talked about a Q3 close. Should we just go ahead and throw in a one quarter of revenue for that business, about the scale you’ve described it or any guidance there would be helpful? And then I’m hoping you can help us a little bit with how to think about the U.S. WATCHMAN launch and how that might contribute in the second half. Thanks.

Sure. I’ll take the first one. On AMS, it’s roughly 100 million a quarter, so that’s – and divide that by the months. And whenever we were to close – whatever your assumption is for closed, just add that in.

Great. And then anything incremental you can help us with how to think about the U.S. WATCHMAN launch?

We’ll spend some time on it Friday. We’re focused on our current 50 sites that did the original IDE trial and we’re opening those sites up again with the training programs. We’ve built up a significant capability with our training and proctoring and we’ll be reopening those sites beginning this quarter in the second half. And then after those first 50 sites are kind of reengaged, we’ll open up 50 new centers. So we have quite tremendous interest in the portfolio and the platform amongst electro-physiologists and interventional cardiologists. A lot of backlog patients that are waiting for it. So hopefully by the end of the year, we anticipate about 100 sites will be up and running with WATCHMAN. And then we see a market opportunity of about 400 sites over the next few years as we continue to develop and open up new centers.

That’s perfect. Thanks, guys.

Lastly, we’ll go to the line of Jayson Bedford, Raymond James & Associates, please go ahead.

Thanks for squeezing me in. I wanted to ask about the peripheral segment. Growth accelerated nicely from back half '14 levels even if we exclude Bayer. It seems like the rollout of – or the broader rollout of drug-coated balloons didn’t have much of an impact on the quarter. So I guess first, is that fair? And then second, did the Bard agreement help out at all in the quarter? Thanks.

The Bard agreement is early, so we haven’t seen – we’ll see more benefit of the Bard deal kind of the back half, if you will, of second quarter and really in the second half of 2015. So really just beginning of tying down the loose ends of that agreement and we’re excited about that, but we didn’t see any impact of the Bard agreement in the first quarter. And the overall PI business, we’re excited about that, because the Bayer integration is going quite well. We’ve done the commercial integrations between the team and so we’re excited about the second half opportunities with our PI business given the portfolio, and very encouraged longer term as you look at the new Eluvia data that was highlighted this morning.

And encouraged with the 9% -- this is Dan, the 9% in the quarter for the Bayer business, because one of the reasons we acquired that business was to get into the fast growing atherectomy segment and to get a leadership position in a thrombectomy market. And with the integration ongoing and seeing that 9% overall growth for PI in the Bayer segment, that was nice to see as well.

Karen, we’ll take just one more please and then conclude.

Thank you. We’ll go to Kristen Stewart, Deutsche Bank, please go ahead.

Hi. Thanks so much for allowing me in last moment. I couldn’t resist but ask Dan a tax question. No, I’m just kidding. Mike I was wondering if you could just talk very high level just with some of the dynamics that we’re seeing from an M&A perspective with Cardinal buying the Cordis business. I’m sure you know Don quite well from the J&J days and just thinking out strategically and kind of what their strategy is from a PPI perspective, how do you view that, if at all, any risk to the base interventional cardiology business, excluding obviously stents?

Yes, so we’ve been competing with Cordis for a number of years. About 70% plus of their business is outside the U.S. And we’ve invested a lot in our interventional cardiology and structural heart and our peripheral business to drive category leadership. We have quite a bit of momentum. And so we’re comfortable on a couple fronts. We’re comfortable but we’re certainly always pushing to grow harder. One is I think we have some highly clinically differentiated platforms with structural heart, with synergy, with atherectomy and thrombectomy and our drug-eluting capabilities. So we think we have very unique innovation there. At the same time, the more commoditized products which is where really Cordis was, are very good, extremely low cost, very excellent manufacturing processes for those capabilities. So, many of those product lines are already commoditized today, many of those products aren’t driving the growth of the business and we manufactured them at great scale at very strong margins. So we always want to be mindful of new competitors but we continue to invest in not only innovation but also in lean best practices and efficiencies to ensure that we can manage some of the pricing challenges that we typically run into.

Okay. Perfect. And then just I guess for clarification purposes on Friday, I know you mentioned in some instances you’d be giving some aspirational goals for 2015 and 2016 for products. Can you just maybe give us an outline of what to expect? Will you be updating your longer term goals beyond 2017 or just kind of going through product by product and giving kind of the 2015 and '16 outlooks?

I think that will give you a reason to come, Kristen. Yes, I wouldn’t want to tell you all the things that we’ll show but good opportunity for people to come on Friday and hear what we have to say.

All right. Well, I’m coming irrespective. See you on Friday.

Okay. Thanks.

All right. With that, we’d like to conclude the call. We look forward to seeing many of you on Friday and thanks for joining us today. We appreciate your interest in Boston Scientific. And before you disconnect, Karen will give you all the pertinent details for the replay. Thanks again.